Prognostic impact of chromogranin A in patients with acute heart failure

Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarker...

Full description

Saved in:
Bibliographic Details
Published inJournal of yeungnam medical science Vol. 38; no. 4; pp. 337 - 343
Main Authors Kim, Hong Nyun, Yang, Dong Heon, Park, Bo Eun, Park, Yoon Jung, Kim, Hyeon Jeong, Jang, Se Yong, Bae, Myung Hwan, Lee, Jang Hoon, Park, Hun Sik, Cho, Yongkeun, Chae, Shung Chull
Format Journal Article
LanguageEnglish
Published Korea (South) Yeungnam University College of Medicine 01.10.2021
영남대학교 의과대학
Subjects
Online AccessGet full text
ISSN2384-0293
2384-0293
2799-8010
DOI10.12701/yujm.2020.00843

Cover

Abstract Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
AbstractList Background Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. Methods We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. Results In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. Conclusion The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. Methods: We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. Results: In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. Conclusion: The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients. KCI Citation Count: 0
Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.BACKGRUOUNDChromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.METHODSWe retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.RESULTSIn-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.CONCLUSIONThe prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure. We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization. In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors. The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.
Author Park, Hun Sik
Kim, Hong Nyun
Kim, Hyeon Jeong
Yang, Dong Heon
Park, Bo Eun
Lee, Jang Hoon
Chae, Shung Chull
Cho, Yongkeun
Jang, Se Yong
Park, Yoon Jung
Bae, Myung Hwan
Author_xml – sequence: 1
  givenname: Hong Nyun
  orcidid: 0000-0002-9903-1848
  surname: Kim
  fullname: Kim, Hong Nyun
– sequence: 2
  givenname: Dong Heon
  orcidid: 0000-0002-1646-6126
  surname: Yang
  fullname: Yang, Dong Heon
– sequence: 3
  givenname: Bo Eun
  orcidid: 0000-0002-5245-9863
  surname: Park
  fullname: Park, Bo Eun
– sequence: 4
  givenname: Yoon Jung
  orcidid: 0000-0001-5132-226X
  surname: Park
  fullname: Park, Yoon Jung
– sequence: 5
  givenname: Hyeon Jeong
  orcidid: 0000-0002-3496-3142
  surname: Kim
  fullname: Kim, Hyeon Jeong
– sequence: 6
  givenname: Se Yong
  orcidid: 0000-0002-4981-879X
  surname: Jang
  fullname: Jang, Se Yong
– sequence: 7
  givenname: Myung Hwan
  orcidid: 0000-0001-7677-4895
  surname: Bae
  fullname: Bae, Myung Hwan
– sequence: 8
  givenname: Jang Hoon
  orcidid: 0000-0002-7101-0236
  surname: Lee
  fullname: Lee, Jang Hoon
– sequence: 9
  givenname: Hun Sik
  orcidid: 0000-0001-7138-1494
  surname: Park
  fullname: Park, Hun Sik
– sequence: 10
  givenname: Yongkeun
  orcidid: 0000-0001-9455-0190
  surname: Cho
  fullname: Cho, Yongkeun
– sequence: 11
  givenname: Shung Chull
  orcidid: 0000-0002-9871-6976
  surname: Chae
  fullname: Chae, Shung Chull
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34233402$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002768387$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqFUctv0zActtAQG2N3TihHOLT4FT8uSNUErNIkEBpny7Gd1l1iBzvZ1P8eNx3TxgEu_ln29_Dn7zU4CTE4AN4iuESYQ_RxP-36JYYYLiEUlLwAZ5gIuoBYkpMn-1NwkfMOQogx4hihV-CUUEwIhfgMXH1PcRNiHr2pfD9oM1axrcw2xT5ukg4-VKuqLIMevQtjru79uK20mUZXbZ1OY9Vq303JvQEvW91ld_Ewz8HPL59vLq8W19--ri9X1wtDKCILTKmljDaUcW6lpKJhXCLecsk5F6JprWSWOiKhaDU02GLdCqKRqyEmxhhyDj4cdUNq1a3xKmo_z01Ut0mtftyslRScMlYX7PqItVHv1JB8r9N-JswHMW1USeBN5xRrIdFCcmprRBGDmlkt6zIdQbU1TdFCR60pDHp_r7vuURBBNReiDoWoQyFqLqRwPh05w9T0zprygUl3zx7y_Cb4bclxpwQTggteBN4_CKT4a3J5VL3PxnWdDi5OWeGaygKlVBTou6dejyZ_qi4AdgSYFHNOrlXGj6XVeLD23b9SwL-I_w3-G9AGzXk
CitedBy_id crossref_primary_10_3390_jpm12060898
crossref_primary_10_3390_jcm12113834
Cites_doi 10.1016/j.amjcard.2016.05.018
10.4070/kcj.2017.0009
10.3346/jkms.2019.34.e133
10.4070/kcj.2018.0349
10.4070/kcj.2018.0373
10.1093/eurjhf/hfq055
10.1111/j.1527-5299.2004.03310.x
10.1152/ajpendo.1991.260.2.e243
10.1053/euhj.2001.2977
10.4070/kcj.2018.0351
10.1080/08880010802435393
10.1093/eurheartj/ehn513
10.1016/j.ahj.2006.05.008
10.4070/kcj.2016.0419
ContentType Journal Article
Copyright Copyright © 2021 Yeungnam University College of Medicine 2021
Copyright_xml – notice: Copyright © 2021 Yeungnam University College of Medicine 2021
DBID AAYXX
CITATION
NPM
7X8
5PM
ADTOC
UNPAY
DOA
ACYCR
DOI 10.12701/yujm.2020.00843
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
Directory of Open Access Journals (DOAJ)
Korean Citation Index
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
CrossRef
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Chromogranin A in acute heart failure
EISSN 2384-0293
2799-8010
EndPage 343
ExternalDocumentID oai_kci_go_kr_ARTI_9874665
oai_doaj_org_article_6f03a8974d514160a6da9560ae315dcb
10.12701/yujm.2020.00843
PMC8688787
34233402
10_12701_yujm_2020_00843
Genre Journal Article
GrantInformation_xml – fundername: Kyungpook National University
GroupedDBID 8JR
AAYXX
ACYCR
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BCNDV
CITATION
EF.
GROUPED_DOAJ
HYE
M~E
PGMZT
RPM
NPM
7X8
5PM
ADTOC
UNPAY
HZB
ID FETCH-LOGICAL-c3413-244d464b4677d9948b67917f7977788bfd96d4e3908fa0c2d2af83a1e5023ccc3
IEDL.DBID DOA
ISSN 2384-0293
IngestDate Sat Jan 04 03:31:02 EST 2025
Wed Aug 27 00:47:01 EDT 2025
Wed Oct 01 16:01:44 EDT 2025
Thu Aug 21 18:23:35 EDT 2025
Fri Jul 11 06:51:53 EDT 2025
Thu Jan 02 22:54:13 EST 2025
Thu Apr 24 23:07:30 EDT 2025
Tue Jul 01 04:12:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Heart failure
Biomarkers
Chromogranin A
Prognosis
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
cc-by-nc
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3413-244d464b4677d9948b67917f7977788bfd96d4e3908fa0c2d2af83a1e5023ccc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
http://www.e-yujm.org/journal/view.php?doi=10.12701/yujm.2020.00843
ORCID 0000-0002-7101-0236
0000-0002-1646-6126
0000-0002-9903-1848
0000-0001-9455-0190
0000-0002-3496-3142
0000-0001-5132-226X
0000-0002-5245-9863
0000-0002-4981-879X
0000-0001-7138-1494
0000-0002-9871-6976
0000-0001-7677-4895
OpenAccessLink https://doaj.org/article/6f03a8974d514160a6da9560ae315dcb
PMID 34233402
PQID 2549688448
PQPubID 23479
PageCount 7
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_9874665
doaj_primary_oai_doaj_org_article_6f03a8974d514160a6da9560ae315dcb
unpaywall_primary_10_12701_yujm_2020_00843
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8688787
proquest_miscellaneous_2549688448
pubmed_primary_34233402
crossref_citationtrail_10_12701_yujm_2020_00843
crossref_primary_10_12701_yujm_2020_00843
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-Oct
PublicationDateYYYYMMDD 2021-10-01
PublicationDate_xml – month: 10
  year: 2021
  text: 2021-Oct
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Journal of yeungnam medical science
PublicationTitleAlternate Yeungnam Univ J Med
PublicationYear 2021
Publisher Yeungnam University College of Medicine
영남대학교 의과대학
Publisher_xml – name: Yeungnam University College of Medicine
– name: 영남대학교 의과대학
References ref13
ref12
ref15
ref14
ref10
ref2
ref17
ref16
ref7
ref9
ref4
ref3
ref6
ref5
Eriksson (ref8) 1989
Benjamin (ref1) 2019
Ottesen (ref11) 2017
References_xml – ident: ref16
  doi: 10.1016/j.amjcard.2016.05.018
– ident: ref4
  doi: 10.4070/kcj.2017.0009
– start-page: e56
  volume-title: Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association
  year: 2019
  ident: ref1
– ident: ref3
  doi: 10.3346/jkms.2019.34.e133
– ident: ref5
  doi: 10.4070/kcj.2018.0349
– ident: ref6
  doi: 10.4070/kcj.2018.0373
– ident: ref13
  doi: 10.1093/eurjhf/hfq055
– start-page: e003675
  volume-title: Glycosylated chromogranin A in heart failure: implications for processing and cardiomyocyte calcium homeostasis
  year: 2017
  ident: ref11
– start-page: 325
  volume-title: Chromogranins: new sensitive markers for neuroendocrine tumors
  year: 1989
  ident: ref8
– ident: ref15
  doi: 10.1111/j.1527-5299.2004.03310.x
– ident: ref7
  doi: 10.1152/ajpendo.1991.260.2.e243
– ident: ref10
  doi: 10.1053/euhj.2001.2977
– ident: ref17
  doi: 10.4070/kcj.2018.0351
– ident: ref14
  doi: 10.1080/08880010802435393
– ident: ref9
  doi: 10.1093/eurheartj/ehn513
– ident: ref12
  doi: 10.1016/j.ahj.2006.05.008
– ident: ref2
  doi: 10.4070/kcj.2016.0419
SSID ssj0002217211
ssj0002808916
Score 2.162462
Snippet Background: Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value...
Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical...
Background Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and...
SourceID nrf
doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 337
SubjectTerms biomarkers
chromogranin a
heart failure
Original
prognosis
의학일반
SummonAdditionalLinks – databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdG9wAvDMRXGKCAeAEpbeI4jv1YEFNBYtoDRePJcvyxde2Sqm2Eyl_PnZtWFBBoL4mU-CL77uy7X3y-I-S1szaV1PDEeaMTxqlMqgzAis41lanJnQmHxD6f8tGYfTovzg9IsT0LE8Iqk6v19TJs47fzWaPtYG79YN1eXYNMKR6EFgwQoPW3yCHHfaUeORyfng2_hUJygiUp2LBuS5KWaRZI-0jaD6R7Jihk6gfDUi_835zMP2Mlb7f1XK-_69nsF0N0ckS-boewiT-Z9ttV1Tc_fsvueOMx3iN3O9c0Hm506T45cPUDMjpbNBiLB8_izYnKuPGxucQovguwc5M6HsZw6fKzLmP8sRtr065cjMWyV7HXEwx9f0jGJx--vB8lXfWFxKBlS8DuW8ZZBStpaaVkouIlYDtfgscIuLnyVnLLXC5T4XVqqKXai1xnrgA3wBiTPyK9uqndExLb0nLKilJaCXiSOeGyCtw4oLVWUEkjMtgKRJkuNTlWyJgphCgoQoWcUcgZFTgTkTc7ivkmLcc_2r5DGe_aYULt8ACYr7r5qbhPcy0AXFnwIDOeam41Qkft8qywporIK9AQNTWTQI_3i0ZNFwpgx0clRck4LyLycqtACmYpbr3o2jXtUiEM50IAFo7I441C7fqDORhzgPERKfdUba_D-2_qyWXIBC7gm7DiRuTtTin_y46nN2l8TO5QDOIJ0YvPSG-1aN1z8MJW1Ytuzv0EJFQvyA
  priority: 102
  providerName: Unpaywall
Title Prognostic impact of chromogranin A in patients with acute heart failure
URI https://www.ncbi.nlm.nih.gov/pubmed/34233402
https://www.proquest.com/docview/2549688448
https://pubmed.ncbi.nlm.nih.gov/PMC8688787
https://www.e-jyms.org/upload/pdf/yujm-2020-00843.pdf
https://doaj.org/article/6f03a8974d514160a6da9560ae315dcb
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002768387
UnpaywallVersion publishedVersion
Volume 38
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Journal of Yeungnam Medical Science, 2021, 38(4), , pp.337-343
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2384-0293
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0002808916
  issn: 2384-0293
  databaseCode: DOA
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2384-0293
  dateEnd: 20221231
  omitProxy: true
  ssIdentifier: ssj0002217211
  issn: 2384-0293
  databaseCode: DOA
  dateStart: 20170101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2384-0293
  dateEnd: 20211231
  omitProxy: true
  ssIdentifier: ssj0002217211
  issn: 2384-0293
  databaseCode: M~E
  dateStart: 20150101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2384-0293
  dateEnd: 20211231
  omitProxy: true
  ssIdentifier: ssj0002217211
  issn: 2384-0293
  databaseCode: RPM
  dateStart: 20180101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUlPbSX0tIvp2lQSy8tmLUlWZaO29KwLTTk0IX0JGR9JJssdtisCfn3nZGdZZeW5tKLDbZkxGikN88aPRHyIXhfaOZkHqKzuZBM500JZMVyy3TheHBpk9iPYzmbi--n1enWUV-YEzbIAw-Gm8hYcKsg6vUA7aUsrPQWY3obeFl51-DsCzC2RaYukqhLojbjuiSri3Jy21_gznOGqVxK8B0cSnL9gC7tKv4t0vwzYfJR317Z2xu7XG6h0dFT8mQMI-l0aP4z8iC0z8nsZNVh3hw8o8PuR9pF6s4x4-4MMGnR0imFy6ilek3xJyy1rl8Higdbr2m0C0xTf0HmR19_fpnl40kJuUMUygGjvZCigVmv9loL1cgaeFisIboDjttEr6UXgetCRVs45pmNitsyVADZzjn-kuy1XRteE-prL5moau01cD8RVCgbCLmgrveKaZaRyZ3djBtlxPE0i6VBOoGWNmhpg5Y2ydIZ-bipcTVIaPyj7Gfsik05FL9OD8AlzOgS5j6XyMh76Ehz6RapPt7POnO5MkARvhmtaiFllZF3d_1sYEThMoltQ9dfG6TMUingrRl5NfT7pj2ol8iBcmek3vGInQbvvmkX50m1W8E3YXbMyKeN79xrjv3_YY435DHDRJyUgXhA9tarPryFSGrdHKZBc0gezo9Ppr9-A-i-G1A
linkProvider Directory of Open Access Journals
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdG9wAvDMRXGKCAeAEpbeI4jv1YEFNBYtoDRePJcvyxde2Sqm2Eyl_PnZtWFBBoL4mU-CL77uy7X3y-I-S1szaV1PDEeaMTxqlMqgzAis41lanJnQmHxD6f8tGYfTovzg9IsT0LE8Iqk6v19TJs47fzWaPtYG79YN1eXYNMKR6EFgwQoPW3yCHHfaUeORyfng2_hUJygiUp2LBuS5KWaRZI-0jaD6R7Jihk6gfDUi_835zMP2Mlb7f1XK-_69nsF0N0ckS-boewiT-Z9ttV1Tc_fsvueOMx3iN3O9c0Hm506T45cPUDMjpbNBiLB8_izYnKuPGxucQovguwc5M6HsZw6fKzLmP8sRtr065cjMWyV7HXEwx9f0jGJx--vB8lXfWFxKBlS8DuW8ZZBStpaaVkouIlYDtfgscIuLnyVnLLXC5T4XVqqKXai1xnrgA3wBiTPyK9uqndExLb0nLKilJaCXiSOeGyCtw4oLVWUEkjMtgKRJkuNTlWyJgphCgoQoWcUcgZFTgTkTc7ivkmLcc_2r5DGe_aYULt8ACYr7r5qbhPcy0AXFnwIDOeam41Qkft8qywporIK9AQNTWTQI_3i0ZNFwpgx0clRck4LyLycqtACmYpbr3o2jXtUiEM50IAFo7I441C7fqDORhzgPERKfdUba_D-2_qyWXIBC7gm7DiRuTtTin_y46nN2l8TO5QDOIJ0YvPSG-1aN1z8MJW1Ytuzv0EJFQvyA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+impact+of+chromogranin+A+in+patients+with+acute+heart+failure&rft.jtitle=Yeungnam+University+journal+of+medicine&rft.au=Kim%2C+Hong+Nyun&rft.au=Yang%2C+Dong+Heon&rft.au=Park%2C+Bo+Eun&rft.au=Park%2C+Yoon+Jung&rft.date=2021-10-01&rft.pub=Yeungnam+University+College+of+Medicine&rft.eissn=2384-0293&rft.volume=38&rft.issue=4&rft.spage=337&rft.epage=343&rft_id=info:doi/10.12701%2Fyujm.2020.00843&rft_id=info%3Apmid%2F34233402&rft.externalDocID=PMC8688787
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2384-0293&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2384-0293&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2384-0293&client=summon